Autres langues Monte Rosa Therapeutics, Inc.

Actions

GLUE

US61225M1027

Temps réel estimé Cboe BZX Autres places de cotation 19:34:17 29/04/2024			Varia. 5j.	Varia. 1 janv.
5,78 ^USD	+8,44 %		+5,09 %	+2,30 %

17:02	MONTE ROSA THERAPEUTICS, INC. : UBS optimiste sur le dossier	ZM
14/03	La perte nette de Monte Rosa Therapeutics au 4ème trimestre se réduit ; les actions baissent	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Monte Rosa Therapeutics : AACR 2024 – The GSPT1 Molecular Glue Degrader MRT-2359 Is Active against Prostate Cancer	03/04
Monte Rosa Therapeutics Q4 Net Loss Narrows; Shares Decline	14/03
Monte Rosa Therapeutics: Q4 Earnings Snapshot	14/03
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	14/03
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/03
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor	11/03
Monte Rosa Therapeutics, Inc. Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1b Pathway Inhibitor	11/03
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	31/01
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024	08/01
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from NASDAQ Biotechnology Index	15/12
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference	21/11
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Monte Rosa Therapeutics: Q3 Earnings Snapshot	09/11
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update	09/11
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases	07/11
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences	27/10/23
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules	26/10/23
Monte Rosa Therapeutics Partners With Roche in Targeting Cancer, Neurological Diseases; Shares Surge Pre-Bell	17/10/23
Monte Rosa Therapeutics : Company Call Presentation - October 17 2023	17/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Monte Rosa Therapeutics, Inc.

Actions

GLUE

US61225M1027

Autres langues

Filtres